Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$3.08
+0.05 (+1.65%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $510.1M · quality 77.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.0B
P/E
44.0x
↑EV/EBITDA
13.2x
↑ROE
1.5%
↑Gross Margin
17.2%
↓Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-2.3%
FCF CAGR
+35.7%
FCF margin
8.5%
FCF / Net income
5.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.03B · net income $101.4M · FCF $510.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.03B | $6.03B | $6.46B | $6.35B | $6.47B |
| Net Income | $101.4M | $101.4M | $287.2M | $224.4M | $272.9M |
| EBITDA | $427.1M | $427.1M | $672.4M | $608.7M | $768.6M |
| EPS | 0.05 | 0.05 | 0.15 | 0.12 | — |
| Gross Margin | 17.2% | 17.2% | 19.0% | 19.2% | 20.9% |
| Operating Margin | 5.7% | 5.7% | 7.2% | 6.0% | 8.7% |
| Net Margin | 1.7% | 1.7% | 4.4% | 3.5% | 4.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | 0.12 | 0.20 | 0.21 |
| Current Ratio | 3.50 | 3.50 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $510.1M | $510.1M | $654.8M | $432.0M | $204.2M |
| Returns | |||||
| ROE | 1.5% | 1.5% | 4.2% | 3.3% | 4.1% |
| Valuation | |||||
| P/E | 44.00 | 44.00 | 29.73 | 40.08 | — |
| EV/EBITDA | 13.16 | 13.16 | 12.72 | 15.54 | 19.82 |
| P/B | 0.87 | 0.87 | 1.25 | 1.32 | 2.19 |
| Growth & Yield | |||||
| Revenue Growth | -6.6% | -6.6% | 1.7% | -1.9% | — |
| EPS Growth | -64.5% | -64.5% | 25.0% | — | — |
| Dividend Yield | 2.9% | 2.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
72.4%
EPS terminal req.
$0.27
Spread vs growth
-136.9%
5Y implied EPS CAGR
44.1%
EPS terminal req.
$0.33
Spread vs growth
-108.5%
10Y implied EPS CAGR
25.9%
EPS terminal req.
$0.53
Spread vs growth
-90.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.0%
Start / end P/E
23.9x → 57.8x
EPS bridge
0.15 → 0.05
Residual
-91.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.